Global Pet Cancer Therapeutics Market to Reach US$ 635.9 Million by 2032, Impelled by Increasing Prevalence of Cancer Among Pets

June 10, 2022 | Healthcare

According to the latest report by IMARC Group, titled “Pet Cancer Therapeutics Market Report by Therapy (Chemotherapy, Radiation Therapy, Immunotherapy, Combination Therapy, and Others), Animal Species (Cats, Dogs, and Others), Cancer Type (Lymphoma, Mast Cell Cancer, Melanoma, Mammary and Squamous Cell Cancer, and Others), End User (Veterinary Hospitals and Clinical Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Region 2024-2032," the global pet cancer therapeutics market reached a value of US$ 295.2 Million in 2023. Pet cancer therapeutics refer to treatment alternatives that have the capability to lessen the effect of cancerous cell tumor growth in domesticated animals. They aid in the treatment of mast cell cancer, lymphoma, melanoma and mammary and squamous cell cancer in cats, dogs and other pet animals. Pet cancer therapeutics mainly include immunotherapy vaccines, targeted therapies, chemotherapy drugs and combination therapies that are employed depending on the type, nature, and stage of the cancer. They gradually neutralize or shrink the cancer cells using various bacteria and plant-based drugs that prevent the tumor from spreading and affecting other parts of the body. They also help relieve other symptoms such as pain and shortness of breath.

Global Pet Cancer Therapeutics Market Trends:

The increasing prevalence of cancer in animals is creating a positive outlook for the market. Cancer is primarily observed in aging animals, with certain breeds possessing higher susceptibility than others. In line with this, the increasing domestication of animals and rising awareness among pet owners regarding pet health is favoring the market growth. Apart from this, rapid advancements in diagnostic procedures and the integration of robotics and artificial intelligence (AI) to reduce the need for surgeries and help veterinarians make informed decisions and treatment plans are providing an impetus to the market growth. Additionally, the launch of highly targeted and specific therapies for treating cancer with minimal side effects is positively impacting the market growth. Other factors, including extensive research and development (R&D) activities to engineer novel formulations and therapies, the rising expenditure capacities of consumers, and an increasing number of veterinary oncologists, are anticipated to drive the market toward growth. On account of the aforementioned factors, the market is expected to reach US$ 635.9 Million by 2032, exhibiting a CAGR of 8.5% during 2024-2032.

Market Summary:

On the basis of the therapy, the market has been divided into chemotherapy, radiation therapy, immunotherapy, combination therapy, and others.
Based on the animal species, the market has been classified into cats, dogs, and others.
On the basis of the cancer type, the market has been divided into lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer, and others.
Based on the end user, the market has been categorized into veterinary hospitals and clinical pharmacies, retail pharmacies, online pharmacies, and others.
Based on the region, the market has been categorized into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and Others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and Others) Latin America (Brazil, Mexico and Others), Middle East and Africa.
The competitive landscape of the industry has also been examined, with the key players being AB Science, Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, ELIAS Animal Health LLC, Karyopharm Therapeutics, Pfizer Inc., Regeneus Ltd., Rhizen Pharmaceuticals AG, Torigen Pharmaceuticals Inc., VetDC Inc., Virbac and Zoetis Inc.

Report Coverage:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Million
Segment Coverage	Therapy, Animal Species, Cancer Type, End User, Region
Region Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	AB Science, Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, ELIAS Animal Health LLC, Karyopharm Therapeutics, Pfizer Inc., Regeneus Ltd., Rhizen Pharmaceuticals AG, Torigen Pharmaceuticals Inc., VetDC Inc., Virbac and Zoetis Inc.
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About US:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Pet Cancer Therapeutics Market to Reach US$ 635.9 Million by 2032, Impelled by Increasing Prevalence of Cancer Among Pets

Purchase options

Single User License ~~$3899~~ $2999
Five User License ~~$4899~~ $3999
Corporate User License ~~$5899~~ $4999

Inquire Before Buying

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.